ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,868.55
-0.22%
Dow Jones
42,392.27
-0.36%
US Dollar vs MXN
20.58095
-0.13%
Brent Oil
75.855
0.00%
Bitcoin
96,766.96
-0.13%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Werewolf Therapeutics Inc (HOWL)

  7. Werewolf Therapeutics Inc (HOWL) Noticias

HOWL

Werewolf Therapeutics (HOWL)

Werewolf Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:HOWL
FechaHoraFuenteTítuloSímboloCompañía
20/11/202407:00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202408:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202408:02GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202408:00GlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
31/10/202407:00GlobeNewswire Inc.Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory DiseasesNASDAQ:HOWLWerewolf Therapeutics Inc
04/10/202408:00GlobeNewswire Inc.Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/09/202407:00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202406:21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202406:05GlobeNewswire Inc.Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
25/06/202406:00GlobeNewswire Inc.Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNASDAQ:HOWLWerewolf Therapeutics Inc
01/06/202408:00GlobeNewswire Inc.Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsNASDAQ:HOWLWerewolf Therapeutics Inc
30/05/202407:00GlobeNewswire Inc.Werewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
24/05/202418:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
23/05/202416:00GlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/05/202406:00GlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
24/04/202409:05GlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
23/04/202407:00GlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
05/04/202415:30GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/04/202415:30GlobeNewswire Inc.Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202406:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202406:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202406:00GlobeNewswire Inc.Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
06/03/202407:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
05/03/202415:30GlobeNewswire Inc.Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024NASDAQ:HOWLWerewolf Therapeutics Inc
09/02/202415:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOWLWerewolf Therapeutics Inc
04/01/202418:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
04/01/202415:05GlobeNewswire Inc.Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of DirectorsNASDAQ:HOWLWerewolf Therapeutics Inc
22/11/202306:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
14/11/202315:25GlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOWL

Su Consulta Reciente

NASDAQ
TSLA
Tesla
AMEX
SPY
SPDR S&P 500
USOTC
BNPQY
BNP Paribas (QX)
FX
EURMXN
Euro vs MXN
NYSE
XOM
Exxon Mobil
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
XRPUSD
Ripple
COIN
SOLUSD
Solana
USOTC
ADDYY
Adidas (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDMXN
US Dollar vs MXN
NYSE
AXP
American Express
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados